Vertex signaled plans for rapid regulatory action after the Phase 3 Rainier trial showed a pronounced reduction in proteinuria for immunoglobulin A nephropathy (IgAN). The company intends to submit a Biologics License Application (BLA) by the end of March seeking potential accelerated approval for povetacicept, a dual BAFF/APRIL inhibitor. An interim analysis reported in the readouts showed approximately a 52% reduction in urine protein-to-creatinine ratio at week 36 compared with placebo—the largest placebo‑adjusted proteinuria response reported in Phase 3 IgAN to date, according to analysts. Vertex positioned the result as best‑in‑class potential and is preparing regulatory filings alongside manufacturing and labeling plans. Competitors and payors will scrutinize long-term renal outcomes and safety data. Vertex’s planned filing could compress timelines for approval in a rare kidney disease with limited disease‑modifying options.